BliNK Therapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 10

Employees

  • Latest Deal Type
  • M&A

BliNK Therapeutics General Information

Description

Developer of novel platform designed to generate therapeutic and diagnostic monoclonal antibodies towards clinically relevant targets. The company's platform uses technology which provides a new way to activate the immune system's B cells, enabling doctors to produce antibodies in response to a specific antigen.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Corporate Office
  • London
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BliNK Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 01-Sep-2018 00.000 Completed Startup
3. Accelerator/Incubator 00.000 Completed Startup
2. Early Stage VC 01-Jan-2015 $781K $2.58M 00.000 Completed Startup
1. Seed Round 13-Jun-2011 $1.8M $1.8M 00.000 Completed Startup
To view BliNK Therapeutics’s complete valuation and funding history, request access »

BliNK Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000 00000.00 00000.00 00 00000.00 00.000
To view BliNK Therapeutics’s complete cap table history, request access »

BliNK Therapeutics Patents

BliNK Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2014250632-B2 Products and methods for stimulating an immune response Inactive 02-May-2008
AU-2014250632-A1 Products and methods for stimulating an immune response Active 02-May-2008
AU-2014250631-A1 Products and methods for stimulating an immune response Active 02-May-2008
AU-2014250631-B2 Products and methods for stimulating an immune response Inactive 02-May-2008
AU-2009241645-A1 Products and methods for stimulating an immune response Active 02-May-2008 A61K39/39
To view BliNK Therapeutics’s complete patent history, request access »

BliNK Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BliNK Therapeutics Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cancer Research Horizons Venture Capital Minority 000 0000 000000 0
Kurma Partners Venture Capital Minority 000 0000 000000 0
Stevenage Bioscience Catalyst Accelerator/Incubator 000 0000 000000 0
To view BliNK Therapeutics’s complete investors history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »